Advanced Drug Delivery Systems in the Management of Cancer

1st Edition - June 23, 2021
Imprint: Academic Press
Editors: Kamal Dua, Meenu Mehta, Terezinha de Jesus Andreoli Pinto, Lisa G. Pont, Kylie A. Williams, Michael Rathbone
Language: English
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 8 5 5 0 3 - 7
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 0 0 7 9 - 9

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers a… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index.

This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations.

Advanced Drug Delivery Systems in the Management of Cancer
is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer.

Cover image
Title page
Table of Contents
Copyright
Dedication
Contributors
Editor biographies
Chapter 1: Introduction to cancer cell biology
Abstract
1: Introduction
2: Types of cancer
3: Pathophysiology of cancer
Chapter 2: Current practice in cancer pharmacotherapy
Abstract
1: Introduction
2: Conclusions
Chapter 3: Current practices in oncology drug delivery
Abstract
1: Introduction
2: Past therapeutic approaches in cancer (1900 and earlier)
3: Current approaches of drug delivery
4: Future directions
Chapter 4: Emerging need of advanced drug delivery systems in cancer
Abstract
1: Introduction
2: Multidrug resistance in cancer cells
3: Toxic effects of chemotherapy
4: Hazardous effects of radiation oncology
5: Polypharmacology in anticancer therapy
6: Advanced drug delivery systems
7: Stimuli-responsive drug delivery systems
8: Conclusion and future perspectives
Chapter 5: Target drug delivery in cancer
Abstract
1: Introduction
2: Ligand-mediated targeting (surface modification)
3: Protein-mediated targeting
4: Carbohydrate-mediated drug delivery
5: Physical targeting via EPR effects
6: Triggered targeting
7: Concluding remarks
Chapter 6: Material and strategies used in oncology drug delivery
Abstract
1: Introduction
2: Materials and stratagem applied in cancer therapy
3: Targeted delivery: Mechanistic pathway
4: Future challenges in cancer therapy
5: Conclusions
Chapter 7: Hydrogel-based drug delivery systems for cancer therapy
Abstract
1: Introduction
2: Hydrogels: An overview
3: Hydrogel-based drug delivery systems for cancer therapy
4: Marketed/patented hydrogel-based drug delivery systems
5: Conclusions and future perspectives
Chapter 8: Recent advances in drug formulation development for targeting lung cancer
Abstract
Acknowledgments
1: Introduction
2: Immunotherapy: Biomolecules targeting lung cancer
3: Lung cancer therapy via inhalation
4: Treatment of metastatic lung cancer
5: The mechanism of drug resistance in lung cancer and its associated treatments
6: Conclusions
Chapter 9: Advanced drug delivery systems in lung cancer
Abstract
1: Introduction
2: Nanoparticle drug delivery
3: Peptide-based nanoparticles
4: Micelles
5: Dendrimers
6: Conclusion
Chapter 10: Advanced drug delivery systems in breast cancer
Abstract
1: Introduction to breast cancer
2: Types of breast cancer
3: Drugs approved/nonapproved for treating breast cancer
4: Conventional delivery systems
5: Advanced drug delivery system in breast cancer
6: Introduction of nanotechnology to breast cancer therapeutics
7: Nano-based advanced DDS in breast cancer
8: Other advanced DDS
9: Antibody-drug conjugates
10: Physiological stimuli responsive-based ADD approach
11: Delivering micro/nanoparticles (drug-loaded or blank)
12: Conclusion
Chapter 11: Advanced drug delivery systems in the treatment of ovarian cancer
Abstract
1: Introduction
2: Pathophysiology of ovarian cancer
3: Nanotools for the treatment of ovarian cancer
4: Conclusion
Chapter 12: Advanced drug delivery systems in blood cancer
Abstract
1: Introduction
2: Types of blood cancer
3: Symptoms of blood cancer
4: Causes of blood Cancer
5: Pathophysiology in blood cancer
6: Blood cancer treatment
7: Challenges in the blood cancer management
8: Blood cancer diagnosis
9: Current theranostic approach
10: Benefits and features of advanced drug delivery system
11: Advance drug delivery tool in the blood cancer management
12: Clinical trials and marketed treatments available for blood cancer
13: Conclusion and future perspective
Chapter 13: Advanced drug delivery systems in kidney cancer
Abstract
1: Introduction
2: Pathophysiology of renal carcinoma
3: Diagnosis
4: Epidemiology
5: Management of kidney cancer
6: Herbal remedies
7: Future perspectives
8: Conclusion
Chapter 14: Advanced drug delivery systems for glioblastoma
Abstract
1: Introduction
2: Glioblastoma and blood–brain barrier
3: Management of glioblastoma (marketed or FDA-approved products/technologies) and challenges
4: Treatment modalities for glioblastoma
5: Emerging therapies for targeting GBM
6: Future perspectives
7: Conclusion
Chapter 15: Advanced drug delivery systems in prostate cancer
Abstract
1: Introduction
2: Targeted drug delivery system
3: Passive and active targeting
4: Nanoparticle delivery systems in prostate cancer
5: Liposome
6: Polymeric nanoparticles and micelles
7: Dendrimers
8: Gold nanoparticles
9: Carbon-based nanoparticles
10: Magnetic nanoparticles
11: Conclusion
Chapter 16: Nanomedicine-based doxorubicin delivery for skin cancer with theranostic potential
Abstract
1: Introduction
2: Doxorubicin—Limitations
3: Nanomedicines—A solution
4: Desired features of a DOX nanocarrier
5: Optimum design of nanoparticulate drug delivery system
6: Methods for development of polymeric nanoparticles
7: Development of DOX-GCPQ nanoformulation
8: Characteristics and features of DOX-GCPQ nanoformulation
9: Commercial viability and marketability of DOX-GCPQ
10: Potential applications of DOX-GCPQ nanoformulation
11: Conclusion
Chapter 17: Advanced drug delivery systems in liver cancer
Abstract
1: Introduction
2: Nanoparticles-mediated drug delivery in HCC
3: Nucleic acids-mediated drug delivery
4: Mesenchymal stem cells (MSCs)-mediated drug delivery
5: Conclusion
Chapter 18: Advanced drug delivery systems in hepatocellular carcinoma
Abstract
1: Introduction
2: Morphology, anatomy, and physiology of normal liver
3: Pathophysiology of HCC
4: Immunobiology of liver in HCC
5: Cell surface proteins/carriers involved in HCC
6: Available treatment for HCC
7: Significance of physicochemical properties of a drug delivery system in HCC
8: Strategies to design ADDS for HCC
9: Conclusion and future perspectives
Chapter 19: Advanced drug delivery systems in oral cancer
Abstract
1: Introduction
2: Advanced drug delivery system in oral cancer
3: Drug vehicles
4: Oral cancer drugs formulation for DDS
5: Conclusion
Chapter 20: Advanced drug delivery system in pancreatic cancer
Abstract
1: Introduction
2: Etiology, pathogenesis, and structure
3: Treatment and challenges
4: Nanotechnology in drug delivery in pancreatic cancer
5: Futuristic approaches to combat pancreatic cancer
Chapter 21: Advanced drug delivery system in colorectal cancer
Abstract
1: Colorectal cancer
2: Drug delivery approaches in colorectal cancer
3: Conclusion
Chapter 22: Current strategies in targeted anticancer drug delivery systems to brain
Abstract
1: Introduction
2: Physiology of blood-brain barrier (BBB)
3: Rationale of a brain-targeted anticancer drug delivery system
4: Transport across the BBB
5: Current strategies to enhance drug delivery against brain cancer
6: Nanoparticle as an emerging strategy for delivery across the BBB
7: Conclusion
Chapter 23: Neuroblastoma: Current advancements and future therapeutics
Abstract
1: Introduction
2: Current advancements in the management of neuroblastoma and their limitations
3: Nanomedicine-based approach in the management of neuroblastoma
4: Drug and gene delivery systems in neuroblastoma
5: Conclusion and future directions
Chapter 24: Nanoparticulate systems and their translation potential for breast cancer therapeutics
Abstract
1: Introduction
2: BC identifiers and the role of P-gp and CYP3A4 in limiting cancer therapeutics
3: Nanoparticulate systems in BC therapeutics
4: Liposomes
5: Solid lipid nanoparticles and nanostructured lipid carriers
6: Nanoemulsions
7: SEDDS
8: Lipid nanocapsules
9: Polymeric micelles
10: Lipoproteins
11: Carbon nanotubes
12: Dendrimers
13: Miscellaneous nanoparticulate systems for BC therapeutics
14: Challenges associated with the clinical translation of nanoparticulate systems
15: Conclusion
Chapter 25: Advancement on nanoparticle-based drug delivery systems for cancer therapy
Abstract
1: Introduction
2: Structure and importance of nanoparticles in cancer therapy
3: Advantage of nanoformulations over other formulations
4: Application of NPs in cancer therapy
5: Conclusion
Chapter 26: Advances in polymeric nanoparticles for drug delivery systems in cancer: Production and characterization
Abstract
1: Introduction
2: Polymeric NPs for drug delivery systems
3: Preparation of polymeric NPs
4: Polymers used in the NPs process
5: API loading and release
6: Characterization of polymeric NPs
7: Applications of polymer NPs
8: Patent research: A briefly overview
9: Future perspectives of polymeric NPs in oncology pathologies
Chapter 27: Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics
Abstract
1: Introduction
2: Challenges in the delivery of cancer chemotherapeutics
3: Methods of preparation of lipid polymer hybrid nanocarriers
4: Applications of polymer lipid hybrid nanoparticles
5: Conclusion
6: Future prospects
Chapter 28: Advancements on microparticles-based drug delivery systems for cancer therapy
Abstract
1: Introduction
2: Materials used for the preparation of microparticles
3: Microparticles for the treatment or diagnosis of cancer
4: Conclusion
Chapter 29: Microparticles for cancer therapy
Abstract
1: Introduction
2: Microparticles: An efficient tool in drug delivery
3: Advances in microparticle technology for cancer therapy
4: Challenges and limitations of microparticle-based cancer therapy
5: Conclusion
6: Future perspectives
Chapter 30: Biosynthetic exosome nanoparticles isolation, characterization, and their diagnostic and therapeutic applications
Abstract
1: Introduction
2: Types of exosomes
3: Isolation and purification of exosomes
4: Characterization of exosomes
5: Exosome nanoparticles: Biomarkers and drug delivery applications
6: Exosomes and cardiovascular disease
7: Summary and perspectives
Chapter 31: Advances in delivery of nanomedicines and theranostics for targeting breast cancer
Abstract
Graphical abstract
1: Background
2: Current trends and challenges in diagnosis as well as treatment of breast cancer
3: Application of nanomedicine in theranostics for breast cancer nanomedicine
4: Nanotechnology advancements for targeted theranostics
5: Nanomedicine for gene therapy
6: Conclusion
Chapter 32: Bioresponsive nano-theranostic approaches for cancer targeting
Abstract
1: Introduction
2: Current situation of cancer
3: General therapeutic strategies
4: Present status of nanomedicine for cancer therapy
5: Bioresponsive nanotheranostics
6: pH-responsive nanotheranostics
7: Redox-responsive nanotheranostics
8: Enzyme-responsive nanotheranostics
9: Miscellaneous bio-responsive nanomedicine
10: Conclusion
Chapter 33: Two-dimensional materials-based nanoplatforms for lung cancer management: Synthesis, properties, and targeted therapy
Abstract
1: Introduction
2: Two-dimensional (2D) nanoplatforms for lung cancer targeting
3: Conclusion
Chapter 34: Cell and gene therapies—Emerging technologies and drug delivery systems for treating brain cancer
Abstract
1: Introduction
2: Current approved medications for brain cancers
3: Preclinical studies on cell and gene therapies
4: Current cell and gene clinical trials for brain cancers
5: Challenges in call and gene therapy for brain cancer
6: Conclusions
Chapter 35: Targeting siRNAs in cancer drug delivery
Abstract
1: Introduction
2: Types of nanoparticles used for siRNA delivery
3: Clinical trials of siRNA by nanoparticles
4: Conclusions
Chapter 36: Targeting micro-ribonucleic acid (miRNA) in cancer using advanced drug delivery systems
Abstract
1: Introduction
2: Advanced drug delivery systems
3: Targeting miRNA in the management of cancer using advanced drug delivery systems
4: Future perspectives and conclusion
Chapter 37: Organic nanocarriers for targeted delivery of anticancer agents
Abstract
1: Introduction
2: Exploiting tumor microvasculature and tumor microenvironment as natural cancer targets
3: Approaches for tumor targeting
4: Organic nanocarriers in cancer targeting
5: Clinical status of organic nanocarriers for cancer treatment
6: Advanced cancer targeting approaches
7: Challenges and future perspectives of organic nanocarriers
8: Conclusion
Chapter 38: Targeting cancer using phytoconstituents-based drug delivery
Abstract
1: Introduction
2: Traditional Indian and Chinese medicine
3: Plant-based natural compounds for treatment of cancers
4: An approach of using phytochemicals or natural products for reducing damage caused by chemotherapy
5: Natural products originated from marine sources
6: Molecular targets of phytochemicals
7: Novel approaches in the field of nanotechnologies with targeting strategies for delivery of bioactives phytoconstituents as a plant pharmaceuticals
8: Conclusion
Chapter 39: Clinical trials in drug delivery for the treatment of cancer
Abstract
1: Introduction
2: Clinical trial advances in drug delivery for cancer treatment
3: Modernization in clinical trial design
4: Advances in clinical trials of nanomedicine-based cancer therapy
5: Challenges and limitations of clinical trials of drug delivery in cancer
6: Challenges for clinical trials of NNMs in cancer therapy
7: Challenges for dietary supplements and foods in clinical trials of cancer therapy
8: Future perspectives in drug delivery for cancer therapy
9: Conclusion
Chapter 40: Future prospects and challenges in cancer drug delivery
Abstract
1: Introduction
2: Worldwide incidence of typical cancers
3: Conclusion
Index

Kamal Dua

Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the University of Technology Sydney (UTS). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2025 and 2024 in Research Magazine by “The Australian” in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

Affiliations and expertise

Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

Meenu Mehta

Meenu Mehta is a research scholar at the Discipline of Pharmacy, Graduate School of Health, the University of Technology Sydney. Her research is focused in the area of pharmaceutical technologies developing novel drug delivery systems for chronic respiratory diseases such as asthma, chronic obstructive lung disease (COPD), and lung cancer. She has obtained her M. Pharm degree in Pharmaceutical Sciences in India, where she has gained working experience in several areas such as drug development, analytical methods, pharmacognosy studies, microwave techniques, and nanotechnology-based novel drug delivery systems. Mehta has received various awards and carries an impressive bibliography of scientific papers published in journals of international repute.

Affiliations and expertise

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

Terezinha de Jesus Andreoli Pinto

Terezinha de Jesus Andreoli Pinto is a Professor at the School of Pharmaceutical Sciences, University of Sao Paulo. Professor Terezinha holds more than 40 years of sound experience in academia and researches on parenterals (formulation, analytical, microbiological, and performance methods) and medical devices. Professor Terezinha authored 180 articles in scientific journals, more than 12 book chapters and also holds two patents. Alongside her career, Professor Terezinha took on management roles in the University, such as being dean of School of Pharmacy for two mandates (2004–2008 and 2012–2016) and also being chair of Deliberative Board of FURP—a pharmaceutical firm that manufactures products from the WHO Essential Medicines list, run by Sao Paulo State Government. Strong scientific skills allied to leadership and management allowed her to establish agreements with internationally prestigious institutions including the University of Alberta, Lisbon, and Bath. Under her supervision, the CONFAR Laboratory was set up, the only Brazilian state university laboratory accredited by the National Institute of Metrology, Quality and Technology (INMETRO) (ISO/IEC 17025) and, authorized by the National Agency of Sanitary Surveillance (ANVISA) and the Ministry of Agriculture, Livestock, and Supplies (MAPA), and is considered a reference both in Brazil and overseas, in the analytical area. Professor Terezinha is also involved with standard-setting activities in agencies such as Brazilian Pharmacopeia (as coordinator of the Brazilian Pharmacopeia Drug Product and Medical Devices technical committee, and currently member of Biological and Biotechnological Products Committee), International Standard Organization (ISO) as Brazilian Association of Technical Norms (ABNT) representative and also the United States Pharmacopeia stakeholder with participation in convention current cycle.

Affiliations and expertise

School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil

Lisa G. Pont

Lisa G. Pont is a Professor in the Discipline of Pharmacy, Graduate School of Health at the University of Technology Sydney. Pont is a pharmacoepidemiologist with expertise in medicine utilization and health service research to evaluate, understand, and improve the quality and safety of medicine use in practice. Her research explores current practices and patterns of medicines use across populations with a focus on the safety and quality of prescribing and medicines use. Throughout her career, Professor Pont has received a number of awards including two national NPS MedicineWise awards in 2014 and in 2016 for her research. She is a registered pharmacist and was awarded the Society of Hospital Pharmacist of Australia Medal of Merit in 2018.

Affiliations and expertise

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

Kylie A. Williams

Kylie A. Williams is a pharmacist and academic leader. She is a founding member of the Graduate School of Health at University of Technology Sydney (UTS), where she is currently the Head of Pharmacy and the Deputy Head of School Learning & Teaching. She has over 25 years of academic experience in learning and teaching, curricula development, research, and academic leadership. Professor Williams leads a research team focused on development, implementation, and evaluation of new models of pharmacy and health service delivery. Alongside her research expertise, Professor Williams is internationally recognized for her curriculum development, and has received a number of teaching grants and awards and has coauthored numerous teaching-related peer-reviewed journal articles, professional books, and educational articles for pharmacists.

Affiliations and expertise

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

Michael Rathbone

Michael J. Rathbone is founder and managing director of his own company, ULTI Pharmaceuticals, New Zealand. He is also an associate of the School, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia. He was formerly professor of Pharmaceutical Technology and dean, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia. Prior to this he was associate professor of Pharmaceutics, School of Pharmacy, Griffith University, Australia where his responsibilities included Acting Head of School. Previous to his appointment at Griffith University, he was the director of Research and General Manager InterAg, New Zealand, where he spearheaded the companies veterinary controlled drug delivery research and directed their national and global collaborative research activities. Dr. Rathbone obtained his undergraduate degree in Pharmacy at Leicester Polytechnic (De Montfort University), UK (1980), and PhD in Pharmaceutics from the University of Aston, Birmingham, UK (1986). Dr. Rathbone has innovated many novel veterinary drug delivery systems, several of which have been registered on the New Zealand, Australian and United States markets. He is a fellow of the Controlled Release Society, has served on the Board of Directors of the CRS and has received several prestigious awards for his contribution to the science and technology of controlled release. He has edited eight books in the area of modified release drug delivery and 10 special theme issues of journals such as Advanced Drug Delivery Reviews and Journal of Controlled Release. His knowledge of the entire spectrum of innovation, product research & development, cGMP analysis, manufacturing scale-up, QC analysis, stability testing, and registration provides him with an extensive overview, and unparalleled experience of the veterinary pharmaceutical industry.

Affiliations and expertise

ULTI Pharmaceuticals, Turangi, New Zealand

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Advanced Drug Delivery Systems in the Management of Cancer

Purchase options

BLOOM INTO SPRING SAVINGS

Institutional subscription on ScienceDirect

Kamal Dua

Meenu Mehta

Terezinha de Jesus Andreoli Pinto

Lisa G. Pont

Kylie A. Williams

Michael Rathbone

Related books